If you got your GLP-1 through a telehealth visit and a monthly mailer, you may have noticed what is missing from the box: any real conversation about food. That gap matters more than the marketing suggests, and it is a useful test of whether the program you signed up for is a medical service or a fulfillment operation.
Here is the access-and-legitimacy angle, stated plainly. Rapid weight loss from semaglutide or tirzepatide does not come off as pure fat. A 2025 joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society notes that a meaningful share of the weight lost on these drugs is lean soft tissue — in the STEP 1 semaglutide trial it cites, roughly 38 percent of the weight lost was lean body mass — and the advisory makes protein intake and resistance training a core priority of care, not an optional extra (AJCN, 2025). A legitimate prescriber should be raising this with you. Many of the cheapest “text a doctor, get a shot” outfits do not.
What the authorities actually say
We are not going to hand you a meal plan, and nothing here is medical advice for your situation. But the published guidance is specific enough to quote.
The four-society advisory notes that higher protein targets — such as 1.2 to 1.6 grams per kilogram of body weight per day — have been proposed during active weight loss, spread through the day rather than loaded into one meal. It is emphatic that protein alone is not enough: preserving muscle also depends on structured resistance training, and it says increased protein “is likely inadequate” without it (joint advisory, AJCN 2025). The same advisory flags nutrient adequacy as a real risk, because GLP-1 medications work partly by cutting appetite, and a much smaller plate can quietly shortchange protein and micronutrients (advisory summary, The Obesity Society).
That is the substance. The point for a telehealth patient is not the exact gram count, which your clinician should personalize — some conditions, such as kidney disease, call for different protein goals. It is that a credible program screens for this and follows up, and a pill-mill does not.
Why the “access” story changed in 2025
For two years, a lot of online GLP-1 access ran through compounded versions, sold cheaply while the branded drugs were in shortage. That door has largely closed. The FDA declared the semaglutide injection shortage resolved on February 21, 2025 (FDA declaratory order), following the tirzepatide resolution in late 2024, and the enforcement grace periods for compounding essentially-copies of both drugs ran out over the spring of 2025.
If a telehealth site is still steering you toward a compounded or “research” GLP-1 as a bargain, that is now a legitimacy question, not a savings question. The FDA has issued specific alerts about dosing errors with compounded injectable semaglutide, including reports of adverse events and hospitalizations tied to accidental overdoses (FDA alert), and warns broadly that compounded and unapproved GLP-1 products do not undergo FDA review for safety, quality, or effectiveness (FDA guidance). A provider that pairs an unvetted drug with zero nutrition support is failing you twice.
How to vet the program, not just the drug
Use the muscle-preservation question as a stress test of the whole service:
- Did intake ask about your current diet, protein, and strength training, or only your weight and card number?
- Is there a named, licensed clinician you can reach with a nutrition question, or only a chat widget?
- Does follow-up include anything besides a refill prompt?
- Are you being upsold a “muscle” peptide or compounded add-on the FDA has not reviewed?
A program that treats protein and resistance training as part of the prescription is behaving like medicine. One that treats them as your problem is behaving like a storefront.
For the deeper science and how-to that sit next to this access question, our sister sites go further than we do: the peptide-and-lean-mass biology at peptidenewsnetwork.com, fasting-and-timing protocols at glpfasting.com, and consumer meal-and-protein how-tos for GLP-1 users at myglptalk.com. Whatever you read, set your actual targets with the clinician who prescribed the drug, and if you do not have one you can actually reach, that is the real problem to fix first.